Soleno Therapeutics (SLNO)

• Market cap: $1.99B
• 1 day: -2.72%
• 5 days: -10.50%
• 1 month: -6.18%
• 3 months: -15.56%
• 6 months: -11.07%
• Year to date: 0.92%
• 1 year: -5.10%
• 5 years: -3.59%
• 10 years: -90.54%
• Sector: Healthcare
• Industry: Electromedical & Electrotherapeutic Apparatus

About: Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Employees: 42

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

208% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 25

96% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 24

15% more funds holding

Funds holding: 142 [Q3] → 163 (+21) [Q4]

3% less call options, than puts

Call options by funds: $120M | Put options by funds: $123M

5.18% less ownership

Funds ownership: 121.26% [Q3] → 116.09% (-5.18%) [Q4]

5% less capital invested

Capital invested by funds: $2.38B [Q3] → $2.25B (-$130M) [Q4]

11% less funds holding in top 10

Funds holding in top 10: 9 [Q3] → 8 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $70 52% upside
• Avg. target: $71 54% upside
• High target: $72 56% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Baird Brian Skorney 22% 1-year accuracy 5 / 23 met price target	56% upside $72	Outperform Reiterated	2 Dec 2024
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 126 / 333 met price target	52% upside $70	Buy Reiterated	2 Dec 2024